A once-weekly oral combination of islatravir plus lenacapavir (Sunlenca) for HIV maintained similarly high rates of virologic ...
Pharmaceutical Technology on MSN
UK approves Gilead’s twice-yearly HIV PrEP drug
Gilead Sciences’ pre-exposure prophylaxis (PrEP) formula of lenacapavir has been approved in the UK as a preventative option ...
A daily preventive pill can be invaluable for people at risk for HIV. But some doctors don't know much about prescribing them. And billing headaches are common. Here's how to overcome those hurdles.
It comes after an injection to prevent HIV, called cabotegravir (CAB-LA) injections, is to be offered to patients on the NHS ...
Gilead Sciences, Inc. GILD has a market-leading HIV franchise, led by flagship HIV therapies — Biktarvy and Descovy. Biktarvy ...
According to the U.S. Centers for Disease Control and Prevention (CDC) and other sources, there are approximately 1.2 million ...
Gilead said its once-daily bictegravir/lenacapavir tablet met non-inferiority vs Biktarvy in phase III ARTISTRY-2, paving the way for filings.
With a second late-stage trial win for its investigational HIV combo in the books, Gilead Sciences is moving full steam ahead ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback